Here's your midday brief for Tuesday, February 24th. I'm Anthony Bansy for the Wall Street Journal.

META has agreed to buy six gigawatts of artificial intelligence computing power from advanced microdevices

in a deal valued at more than $100 billion. The companies say the agreement includes warrants for

meta to buy up to 10% of AMD stock if certain milestones are met. The chips, which will be

custom built for meta, will be used to power its data centers for specific AI tasks, like

responding to user queries. The deal itself is a big move for AMD as it challenges

NVIDIA in the market for selling the microchips, powering the AI boom. We're exclusively

reporting that Danish drug maker Novo Nordisk plans to slash U.S. list prices for its popular

weight loss and diabetes drugs by up to half, starting next year. According to an interview

with a company executive, Ozambic and Wagovi will both list for $675 a month at the beginning of

2027. The move escalates a price war with its American rival, Eli Lilly, as both companies face

pressure over high out-of-pocket costs for patients.

And the conference board says consumer confidence edged higher in February, though it remained

below the levels seen in late 2024. The group's index rose to 91.2 this month, which outperform

the expectations of economists pulled by the Wall Street Journal.

But analysts say shoppers remain concerned about inflation as the Federal Reserve's preferred price

index rose 0.4% in December.

Heads up, an artificial intelligence tool helped us make this episode by creating summaries

that were based on WSJ reporting and then reviewed and adapted by an editor.

We'll have more coverage of the day's news on WSJ's What's News podcast.

You can edit to your playlist on your smart speaker or listen and subscribe wherever you get your podcasts.